New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
06:31 EDTXLRNAcceleron Pharma price target raised to $65 from $35 at Piper Jaffray
Piper Jaffray raised its price target for Acceleron Pharma shares to $65 ahead of the clinical data read-outs it expects to start in June. Piper expects share value to be driven by the company's clinical progress for dalantercept, as it sees blockbuster potential in multiple cancers. The firm reiterates an Overweight rating on Acceleron.
News For XLRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
11:49 EDTXLRNPiper Jaffray healthcare analysts to hold an analyst/industry conference call
Subscribe for More Information
November 13, 2014
07:10 EDTXLRNSociety for NeuroOncology to hold a meeting
Subscribe for More Information
November 10, 2014
15:54 EDTXLRNAmerican Society of Nephrology to hold a conference
Subscribe for More Information
November 7, 2014
07:32 EDTXLRNAcceleron reports Q3 EPS (25c), consensus (27c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use